KMC Speciality (524520)
Fast GrowerFairStock Score: 46/100 — MIXED
Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹81.32 |
| Market Cap | ₹1,333.88 Cr |
| P/E Ratio | 38.15 |
| ROCE | 17.37% |
| ROE | 23.96% |
| Dividend Yield | 0% |
| Profit Growth | 82.82% |
| Debt/Equity | — |
| Sales Growth | 33.74% |
| 52-Week Range | ₹65.01 — ₹97.6 |
| Sector | Healthcare Services |
| Book Value | ₹9.69 |
Strengths
- Strong profitability with ROE of 23.96% and ROCE of 17.37%
- Rapid growth: sales up 33.74% and profit up 82.82%, with PEG of 0.65
- Piotroski F-Score of 7/9 indicates healthy financials and earnings quality
- Latest quarter profitable: ₹82 Cr sales and ₹14 Cr net profit
Concerns
- Rich valuation: P/E of 38.15 and P/B of 8.39 against book value of ₹9.69 leaves little margin of safety
- Zero dividend yield means no cash return to shareholders
- Promoter holding and debt/equity are not disclosed, so governance and leverage risk cannot be assessed
- FairStock Score of 43/100 is mixed despite strong headline growth
AI Analysis
Let me look at KMC Speciality the way I look at any business—through numbers, not noise. The company earns a return on equity of 23.96% and a ROCE of 17.37%, so it is converting capital into profits efficiently. Book value is only ₹9.69, yet the market pays ₹81.32, a price-to-book of 8.39; that is a rich price, but quality often demands a premium. Sales grew 33.74% and profits jumped 82.82%, and the Piotroski F-Score of 7/9 suggests the earnings quality is backed by solid fundamentals. On the surface, a P/E of 38.15 looks expensive, but the PEG ratio of 0.65 tells me the growth is doing a lot of the heavy lifting. I won't overpay for momentum; I need the growth to continue. The latest quarter shows sales of ₹82 crore and net profit of ₹14 crore, so the engine is still running. Still, I have reservations. There is no dividend—zero yield—so my return wholly depends on reinvestment and eventual valuation. Promoter holding is not disclosed in the data I have; I cannot judge whether the people running the shop have enough skin in the game. Debt-to-equity is also not available, leaving a gap in my safety check. FairStock Score of 43/100 is mixed; the market is paying for a wonderful business, but I must ask whether it is a wonderful price. If growth moderates, a high P/E leaves little margin of safety. I would keep it on my watch list, not my buy list, unless the price falls or earnings catch up with optimism.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer